Evidence map›Paper›PMID 40318680›Full record

ReviewThe lancet. Diabetes & endocrinology2025

Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement.

Sophie Leboulleux, Laura Boucai, Naifa Busaidy, Cosimo Durante, James A Fagin, Sasan Fazeli, Andrew G Gianoukakis, Bryan R Haugen, Hyunseok Kang, Bhavana Konda and 7 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The lancet. Diabetes & endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Disulfiram metabolite Cu(DDC)EBioMedicine · 2026
    Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Sophie LeboulleuxDepartment of Medicine, Endocrinology and Diabetology Service, Geneva University Hospitals and Univerisity of Geneva, Geneva, Switzerland. Electronic address: sophie.leboulleux@hug.ch.
Laura BoucaiDepartment of Medicine, Endocrinology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Naifa BusaidyDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Cosimo DuranteDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
James A FaginDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sasan FazeliDepartment of Clinical Diabetes, Endocrinology & Metabolism, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Andrew G GianoukakisDivision of Endocrinology, Diabetes and Metabolism, David Geffen School of Medicine at UCLA Harbor-UCLA Medical Center, Los Angeles, CA, USA.
Bryan R HaugenDivision of Endocrinology, Metabolism and Diabetes, University of Colorado School of Medicine, Aurora, CO, USA.
Hyunseok KangDepartment of Medicine, University of California at San Francisco, San Francisco, CA, USA.
Bhavana KondaDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Theodore W LaetschCenter for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Laura LocatiMedical Oncology Unit, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy.
Mabel RyderDivision of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN, USA.
Christine SpitzwegDepartment of Internal Medicine IV, LMU Munich, Germany; Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, Minnesota, USA.
Francis P WordenDepartment of Internal Medicine, Division of Hematology and Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
Lori WirthHarvard Medical School, Boston, MA, USA; Center for Head and Neck Cancers, Massachusetts General Hospital, Boston, MA, USA.
Alan HoDepartment of Medicine, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY, USA; Head and Neck Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Alan Ashworth · 1999 to 2026
$209.7M
Improving efficacy of radioiodine treatment of thyroid cancerR01CA249663 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI FAGIN, JAMES A, HO, ALAN L. · 2021 to 2025
$2.3M
NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA082103NCI NIH HHS R01 CA249663
6 · The paper itself

Abstract

In patients with follicular cell-derived thyroid cancer that have distant metastases and no iodine uptake, redifferentiation-ie, the restoration of tumoural

Indexed as

Iodine RadioisotopesThyroid NeoplasmsHumansIodine Radioisotopes

Identifiers

PMID40318680
PMCPMC13011886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.